Jeito Capital Strengthens Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent.

0 0 2 minutes read

Jeito Capital Strengthens Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent.

Article content

Sarah has an MPA in Economics and Political Science from Princeton University and a bachelor’s degree in international relations from Pomona College. She is a member of Women Innovating Together in Healthcare (WITH) and sits on the steering committee.

Article content

Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said:

Article content

“We are pleased to welcome Elaine and Sarah, whose backgrounds and expertise will strengthen Jeito’s capabilities in a highly complementary manner. Their extensive and widely recognized experience in the biopharma and investment sectors will help strengthen our unique model, which integrates core expertise across drug development to support the expansion of our portfolio companies. new to patients.”

Article content

Elaine Caughey, Partner, Business Development and Investor Relations, added:

Article content

“I am very pleased to join Jeito and contribute to this new phase of its development. With significantly strengthened financial resources following the last record closing of the latest fund, a highly respected team, and a high-quality portfolio, I am happy to bring my experience to Jeito and its portfolio companies, supporting them in reaching their full potential and creating value for patients.”

Article content

Sarah Shackelton, Partner, Talents, said:

Article content

“Talent is one of the most powerful drivers of a company’s value – but only if it is considered a real strategic input, not an afterthought. Jeito has achieved an outstanding record in a short period of time, supporting pioneering companies that bring new treatments to patients. Joining a team with that kind of ambition, drive and understanding of talent is an easy decision that will develop leadership that will improve my skills. Jeito’s companies and clinical programs are moving forward, and in promoting a culture of success throughout portfolios.”

Article content

About Jeito Capital:

Article content

Jeito Capital is the world’s leading Private Equity fund with a patient-driven approach to financing and accelerating the development and growth of medical innovation. With 1.6 billion euros under management, Jeito empowers and supports management with its experts, an integrated team, with many skills and with significant investments to ensure the growth of companies, to create market leaders in their therapeutic areas with rapid access to patients around the world, especially in Europe and the United States. Jeito has built a diverse portfolio of clinical biopharmas with high-quality innovations that address high unmet needs. Jeito Capital is based in Paris and has a presence in Europe and the United States.

Article content

For more information, please visit www.jeito.life or follow us on LinkedIn.

Article content

View the source version on businesswire.com:

Article content

https://www.businesswire.com/news/home/20260505599856/en/

Article content